Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04569591 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DDAVP for Pituitary Adenoma

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 1247 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. 3 versions Re-verified since Mar 25, 2026, no change to tracked fieldsv1245-v1247
  2. Study Status, Eligibilityv1244
  3. Re-verified, no change to tracked fieldsv1243
  4. Start date changed from estimate of Mar 15, 2026 to Mar 9, 2026v1242
  5. Start date: Mar 12, 2026 to Mar 15, 2026 Eligibility criteria expanded, about 12 wordsv1241 Show 1 more changeShow less
    • Eligibility criteria expanded, about 12 words

    See this version in full on ClinicalTrials.gov ↗

Show 43 earlier versionsHide 43 earlier versions
  1. Start date: Mar 11, 2026 to Mar 12, 2026v1240
  2. Trial status: Not Yet Recruiting to Recruiting Start date: Mar 10, 2026 to Mar 11, 2026 · Site details revisedv1239 Show 2 more changesShow less
    • Start date: Mar 10, 2026 to Mar 11, 2026
    • Site details revised
  3. Start date: Mar 9, 2026 to Mar 10, 2026v1238
  4. Primary and study completion dates: Apr 20, 2026 to Feb 26, 2028 Primary endpoint revised · Start date: Mar 5, 2026 to Mar 9, 2026 · Interventions: Acthrel (Drug) to Desmopressin acetate (Drug) · 2 morev1237 Show 5 more changesShow less
    • Primary endpoint revised
    • Start date: Mar 5, 2026 to Mar 9, 2026
    • Interventions: Acthrel (Drug) to Desmopressin acetate (Drug)
    • Secondary endpoint revised
    • Study title shortened, about 10 words

    See this version in full on ClinicalTrials.gov ↗

  5. Start date: Mar 4, 2026 to Mar 5, 2026v1236
  6. Start date: Mar 3, 2026 to Mar 4, 2026v1235
  7. Start date: Mar 2, 2026 to Mar 3, 2026v1234
  8. Start date: Mar 1, 2026 to Mar 2, 2026v1233
  9. Start date: Feb 26, 2026 to Mar 1, 2026v1232
  10. Start date: Feb 25, 2026 to Feb 26, 2026v1231
  11. Start date: Feb 24, 2026 to Feb 25, 2026v1230
  12. Start date: Feb 23, 2026 to Feb 24, 2026v1229
  13. Start date: Feb 22, 2026 to Feb 23, 2026v1228
  14. Start date: Feb 9, 2026 to Feb 22, 2026v1227
  15. Start date: Feb 3, 2026 to Feb 9, 2026v1226
  16. Start date: Feb 2, 2026 to Feb 3, 2026v1225
  17. Start date: Feb 1, 2026 to Feb 2, 2026v1224
  18. Start date: Jan 29, 2026 to Feb 1, 2026v1223
  19. Start date: Jan 28, 2026 to Jan 29, 2026v1222
  20. Start date: Jan 27, 2026 to Jan 28, 2026v1221
  21. Start date: Jan 26, 2026 to Jan 27, 2026v1220
  22. Start date: Jan 22, 2026 to Jan 26, 2026v1219
  23. Start date: Jan 21, 2026 to Jan 22, 2026v1218
  24. Start date: Jan 20, 2026 to Jan 21, 2026v1217
  25. Start date: Jan 19, 2026 to Jan 20, 2026v1216
  26. Start date: Jan 18, 2026 to Jan 19, 2026v1215
  27. Start date: Jan 15, 2026 to Jan 18, 2026v1214
  28. Start date: Jan 14, 2026 to Jan 15, 2026v1213
  29. Start date: Jan 13, 2026 to Jan 14, 2026v1212
  30. Start date: Jan 12, 2026 to Jan 13, 2026v1211
  31. Start date: Jan 11, 2026 to Jan 12, 2026v1210
  32. Start date: Jan 8, 2026 to Jan 11, 2026v1209
  33. Start date: Jan 6, 2026 to Jan 8, 2026v1208
  34. Primary and study completion dates: Dec 31, 2025 to Apr 20, 2026 Start date: Dec 30, 2025 to Jan 6, 2026v1207 Show 1 more changeShow less
    • Start date: Dec 30, 2025 to Jan 6, 2026
  35. Start date: Dec 29, 2025 to Dec 30, 2025v1206
  36. Start date: Dec 28, 2025 to Dec 29, 2025v1205
  37. Start date: Dec 25, 2025 to Dec 28, 2025v1204
  38. Start date: Dec 24, 2025 to Dec 25, 2025v1203
  39. Start date: Dec 23, 2025 to Dec 24, 2025v1202
  40. Start date: Dec 22, 2025 to Dec 23, 2025v1201
  41. Start date: Dec 21, 2025 to Dec 22, 2025v1200
  42. Start date: Dec 18, 2025 to Dec 21, 2025v1199
  43. Start date: Dec 16, 2025 to Dec 18, 2025v1198
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed as a single institution trial. The study utilizes safe and clinically-validated tools for preoperative workup of patients with small pituitary tumors. DDAVP stimulation and 18F-labeled fluoro-deoxyglucose (FDG) uptake for PET-imaging will be used to detect MRI-negative pituitary adenomas in patients with Cushing s disease. Patients who have MRI-negative pituitary microadenomas will undergo FDG PET-imaging with DDAVP stimulation. Intravenous FDG will be given approximately four hours following DDAVP administration. Within 12 weeks after completion of the FDG high-resolution PET scan, patients will undergo surgical resection of the pituitary adenoma. Surgical and histological confirmation of adenoma location will be noted. All images will be read independently by neuroradiologists blinded to clinical and histopathological outcomes. The diagnostic and localization accuracy of PET-imaging will be assessed by comparing the PET findings with histopathology.
Trial Details
NCT Number NCT04569591
Lead Sponsor National Institute of Neurological Disorders and Stroke (NINDS)
Conditions Cushing's Disease, Pituitary Adenoma
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov